Computational fluid dynamics modelling in cardiovascular medicine

Paul D Morris,1,2,3 Andrew Narracott,1,2 Hendrik von Tengg-Kobligk,4 Daniel Alejandro Silva Soto,1,2 Sarah Hsiao,1 Angela Lungu,1,2 Paul Evans,1,2 Neil W Bressloff,5 Patricia V Lawford,1,2 D Rodney Hose,1,2 Julian P Gunn1,2,3

ABSTRACT
This paper reviews the methods, benefits and challenges associated with the adoption and translation of computational fluid dynamics (CFD) modelling within cardiovascular medicine. CFD, a specialist area of mathematics and a branch of fluid mechanics, is used routinely in a diverse range of safety-critical engineering systems, which increasingly is being applied to the cardiovascular system. By facilitating rapid, economical, low-risk prototyping, CFD modelling has already revolutionised research and development of devices such as stents, valve prostheses, and ventricular assist devices. Combined with cardiovascular imaging, CFD simulation enables detailed characterisation of complex physiological pressure and flow fields and the computation of metrics which cannot be directly measured, for example, wall shear stress. CFD models are now being translated into clinical tools for physicians to use across the spectrum of coronary, valvular, congenital, myocardial and peripheral vascular diseases. CFD modelling is appropriate for minimally-invasive patient assessment. Patient-specific (incorporating data unique to the individual) and multi-scale (combining models of different length- and time-scales) modelling enables individualised risk prediction and virtual treatment planning. This represents a significant departure from traditional dependence upon registry-based, population-averaged data. Model integration is progressively moving towards ‘digital patient’ or ‘virtual physiological human’ representations. When combined with population-scale numerical models, these models have the potential to reduce the cost, time and risk associated with clinical trials. The adoption of CFD modelling signals a new era in cardiovascular medicine. While potentially highly beneficial, a number of academic and commercial groups are addressing the associated methodological, regulatory, education- and service-related challenges. It can predict physiological responses to intervention and compute previously unmeasurable haemodynamic parameters.4 As CFD modelling continues to translate into clinical tools, it is important that clinicians understand the principles, benefits and limitations of these techniques. This article explores these topics using state-of-the-art examples in key clinical areas, highlighting applications likely to impact clinical practice within the next 5 years (table 1).

WHAT IS CFD?
CFD is a specialist area of mathematics and a branch of fluid mechanics. It is used in the design of many safety-critical systems, including aircraft and vehicles, by solving differential equations to simulate fluid flow. A glossary of useful terms is provided in table 2.

For incompressible flows, almost all CFD analyses solve the Navier-Stokes and continuity equations which govern fluid motion. These equations are non-linear, partial differential equations based upon the principle of conservation of mass and momentum. Simplification of these equations yields familiar formulae (eg, those of Bernoulli and Poiseuille); but for complex geometries analytical solutions are not possible, so specialised software applications (CFD solvers) calculate approximate numerical solutions. Non-linearity, due to convective fluid acceleration, makes this challenging, especially in three dimensional (3D) models; so CFD analyses require significant computational power and time.

CFD MODEL COMPLEXITY
The applications reviewed in this paper focus on 3D CFD analyses of local regions of the vasculature because this is where promising applications are beginning to translate and impact upon clinical medicine. There is a long history of simplification of the governing equations to lower spatial dimensions. Table 3 summarises the relationship between these approaches and provides clinical examples of their use.

2D analyses typically assume symmetry of the solution about the central axis, 1D models capture variation of the solution along the axial direction only, and 0D representations lump the behaviour of vascular regions into a model with no spatial dimensions, hence the term ‘lumped-parameter models’. Due to the breadth of the literature covering application of these techniques to cardiovascular haemodynamics, the interested reader is referred to recent reviews of the state-of-the-art.45 46

INTRODUCTION
Computational fluid dynamics (CFD) is a well-established tool used in engineering, in many areas of which it has become the primary method for design and analysis. Bioengineers have adopted CFD to study complex physiological flows and have demonstrated their potential.1 There is increasing interest in applying these methods in cardiovascular medicine.2 3 CFD-based techniques are being used to build complex computer representations (in silico models) of the cardiovascular system in health and disease. CFD modelling is a new field within cardiovascular medicine, enhancing diagnostic assessment, device design and clinical trials.
Table 1: Summary of CFD modelling applications in cardiovascular medicine

<table>
<thead>
<tr>
<th>Area</th>
<th>Clinical applications</th>
<th>Data and evidence</th>
<th>Potential clinical impact</th>
<th>Limitations and challenges</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary artery disease and physiology</td>
<td>Models based upon coronary angiography (CT invasive) to compute physiological coronary lesion significance less invasively</td>
<td>Multiple trials demonstrating broadly good agreement between standard and CFD-derived FFR (vFFR). Lesion significance established in ~80–90%</td>
<td>Widened access to the benefits of physiological lesion assessment; vFFR lacks the practical limitations that restrict use of the invasive technique. Virtual stenting enables planning and selection of optimal treatment strategy</td>
<td>Accurate vessel reconstruction and patient-specific tuning of the model boundary conditions (especially those of myocardial resistance)</td>
<td>5 6 7 8</td>
</tr>
<tr>
<td>Valve prostheses</td>
<td>Evaluation and optimisation of prosthetic valve design from a haemodynamic perspective</td>
<td>Included in the design dossier given to RA for approval before use in humans. Third party, comparative studies are in engineering literature</td>
<td>CFD modelling enables the best design, yielding the optimal haemodynamics and lowest achievable risk of design-related thrombosis and thromboembolism</td>
<td>Dependence upon validity of models to interpret fluid stresses in terms of thrombogenic/haemolytic potential. Primarily relates to mechanical valves. Tissue valve leaflets remain challenging to model</td>
<td>9 10 11</td>
</tr>
<tr>
<td>Native valve haemodynamics in health and disease</td>
<td>Non-invasive computation and quantification trans-valvular pressure drop and regurgitant fraction from CT imaging</td>
<td>Accurate 3D simulations in patient-specific models with valves in open and closed states to predict transvalvular dynamics in diseased states</td>
<td>Improved objective assessment and surveillance of valve disease from non-invasive imaging data</td>
<td>Requires high quality 3D imaging or patient data—not routinely generated. Balancing the requirement for complex dynamic simulation (FSI) vs simpler models (valve open/closed)</td>
<td>12 13</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>Provides quantitative haemodynamic data for non-invasive imaging to emphasise the significance of findings. Virtual therapy simulation/predictions</td>
<td>No published outcome trials, only single centre experiences and small cohorts using different boundary condition and computational methods</td>
<td>To better predict aneurysm progression and risk of rupture. Prediction of putative therapeutic effects. Individualised care and reduction in costs for unnecessary follow-up imaging and visits</td>
<td>Impact of low image contrast structures of aortic aneurysm (eg, wall, thrombus) as well as wall motion needs to be further assessed. CFD alone is probably limited and needs to be complemented by, for example, FSI</td>
<td>3 14 15 16</td>
</tr>
<tr>
<td>Aortic dissection</td>
<td>Pathophysiological conditions in true and false lumen computed from non-invasive boundary conditions (CT and MRI +PC). Effects of virtual therapy.</td>
<td>No published outcome trials, only single centre experiences and small cohorts using different boundary conditions and computational methods</td>
<td>Computed pressure and flow conditions used to guide (semi-) invasive therapeutic procedure decisions. Physiological effects of therapies can be simulated and better predicted</td>
<td>Significant early and late re-modelling of the dissected wall. Entry, re-entry and communication channels create a complex computational scenario. CFD alone might be limited. A potential role for FSI</td>
<td>17 18 19</td>
</tr>
<tr>
<td>Stent design</td>
<td>Prediction of WSS and related metrics that influence endothelial function and NH due to stent-induced haemodynamic disturbance</td>
<td>Turbulent or disturbed laminar flow reduces WSS stimulating adverse vessel remodelling. NH preferentially accumulates in these regions</td>
<td>Not possible to measure arterial WSS in vivo, especially in the vicinity of stent struts post-PCI. Modelling provides detailed analysis of flow, and the influence of stent design through patient-specific reconstructions, enabling the optimal stent design to be achieved</td>
<td>High resolution imaging, vessel reconstruction and boundary conditions are challenging. CFD simulations demand fine computational meshes and time-resolved pulsatility. Run-times are long, even with high performance computing</td>
<td>20 21 22 23 24 25 26 27</td>
</tr>
<tr>
<td>Cerebral aneurysm</td>
<td>Prediction of intra-aneurysmal flow, stasis, jet impingement and WSS from MRI and CT cerebral angiography data</td>
<td>Published data on association between WSS, aneurysm initiation, growth, and potentially rupture</td>
<td>Detailed, individualised haemodynamic analysis with potential for risk prediction. Impact of putative treatments on local haemodynamics evaluated in silico</td>
<td>Difficulty interpreting complex and detailed WSS results. Understanding how results translate to rupture risk. Validation of rupture predictions—a rare event</td>
<td>4 28 29</td>
</tr>
<tr>
<td>Pulmonary hypertension (PH)</td>
<td>Greater insights into complex PH physiology. Increasing interest in non-invasive diagnosis and monitoring of response to treatment</td>
<td>Models based on MR flows demonstrated to differentiate between healthy volunteers and to stratify PH subcategories</td>
<td>Imaging-based modelling of pulmonary haemodynamics can reduce the requirement for right heart catheterisation. Models show association between reduced WSS and invasive PH metrics. PH subtype characteristics simulated to understand the structural changes contributing to increased PAP</td>
<td>Spatial resolution of imaging and segmentation protocols. The use of a pressure surrogate measure. The presence of many outlets requiring many measurements to tune the outflow boundary conditions</td>
<td>30 31 32 33</td>
</tr>
<tr>
<td>Arterial wall shear stress (WSS)</td>
<td>WSS mapping, cross-referenced with WSS-based surrogates</td>
<td>An abnormal WSS pattern has been correlated with</td>
<td>Ultimate understanding of the development and evolution of the disease and potential clinical applications</td>
<td>A detailed vascular geometry is essential for an accurate prediction</td>
<td>20 21 22 25</td>
</tr>
</tbody>
</table>

Continued
### Model Construction

**CFD model construction and solution can be described in seven stages (figure 1):**

1. **Clinical imaging**
   - A range of medical imaging modalities can be used, including ultrasound, CT, MRI and X-ray angiography. Imaging must provide sufficient anatomical and physiological detail, in an appropriate format and quality, to enable segmentation and data extraction.

2. **Segmentation and reconstruction**
   - Segmentation methods convert medical images into silico geometries which define the physical bounds of the model region of interest. If images are acquired over a cardiac cycle, anatomical motion can be tracked over segmented regions.

3. **Discretisation**
   - Spatial discretisation, or ‘meshing’, divides the geometry into a number of discrete volumetric elements or cells. Temporal discretisation divides the solution into discrete time steps. The accuracy and numerical stability of the analysis are influenced by both spatial and temporal refinement. The fabrication of the mesh, and the level of mesh refinement, are influenced by case- and context-specific factors. The mesh and timestep (i.e., spatio-temporal discretisation) must be refined enough to capture the important haemodynamic behaviour of the modelled compartment (the final solution should be independent of mesh parameters), but without excessive refinement because this impacts negatively on computational resource and solution time (see online supplementary table S1).

4. **Boundary conditions**
   - Because it is impossible to discretise the entire cardiovascular system, the region to be analysed will have at least one inlet and one outlet. To enable CFD analysis, the physiological conditions at the wall and inlet/outlet boundaries must be specified. Boundary conditions are a set of applied physiological parameters (which may vary over time) that define the physical conditions at the inlets, outlets and walls. They may be based on patient-specific data, population data, physical models or assumptions.

### Table 1: Area, Clinical applications, Data and evidence, Potential clinical impact, Limitations and challenges, References

<table>
<thead>
<tr>
<th>Area</th>
<th>Clinical applications</th>
<th>Data and evidence</th>
<th>Potential clinical impact</th>
<th>Limitations and challenges</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Heart failure</strong></td>
<td>Models based upon CT and MR help compute haemodynamics and the spatio-temporal distributions of pressure and myocardial stress/stain</td>
<td>CFD/FSI models replicate realistic pathophysiology in models of health and disease (e.g., HFREF, HFRF, HCM, DCM, and RWMA post-MI)</td>
<td>Additional haemodynamic data potentially enables early diagnosis and stratifies disease phenotypes and severities. Characterising complex vortex flows identifies areas of flow stagnation and thrombus risk.</td>
<td>Resolution of imaging and reconstruction (representing trabeculae and papillary muscles). Tuning with realistic boundary conditions. Requirement for FSI in many models.</td>
<td>2 3 4 5 6 7 8 9 10 11</td>
</tr>
<tr>
<td><strong>CRT</strong></td>
<td>Coupled electro-mechanical models of the ventricle incorporating CFD (multi-physics models) used to investigate heart function</td>
<td>Published reports of accurate patient-specific haemodynamic simulations with sufficient detail to optimise CRT before surgical intervention</td>
<td>Improved selection of CRT responders. Simulation and selection of optimal tuning of device settings and lead placement on an individual case basis.</td>
<td>Uncertainties and assumptions regarding boundary conditions and the range of clinical measurements required for parameterisation. Mesh generation, prolonged computation times.</td>
<td>12 13 14 15 16 17 18 19 20 21</td>
</tr>
<tr>
<td><strong>VADs</strong></td>
<td>Generic optimisation of pump design. Patient-specific models can aid implantation strategy and tuning of output according to patient physiology</td>
<td>Published models describing haemodynamic influences of catheter placement and minimisation of adverse haemodynamic effects</td>
<td>Pump tuning to ensure periodic opening and closing of AV, preventing leaflet fusion. Personalised catheter placement planning (prediction and avoidance stasis and thrombus formation).</td>
<td>Post-implantation imaging artefact limits modelling. Optimising performance requires the balance of multiple competing factors. As for all cardiac electromechanical models, selection of appropriate patient specific parameters is difficult due to sparsity of data.</td>
<td>22 23 24 25 26 27 28 29 30 31</td>
</tr>
<tr>
<td><strong>Congenital heart disease</strong></td>
<td>CFD simulates haemodynamics which are complex and hard to predict in the context of a diverse and heterogeneous range of disease phenotypes</td>
<td>Range of models described, including reduced order, 3D CFD, FSI and multiscale, particularly in the context of univentricular circulation, aortic and pulmonary malformations</td>
<td>Modelling enables greater understanding of systemic and regional haemodynamics and the prediction of response to putative surgical or device-based treatments which often involve significant modifications to the circulatory tree.</td>
<td>Acquisition and application of model parameters and boundary conditions from patient and literature data. The ultimate personalisation challenge.</td>
<td>32 33 34 35 36 37 38 39 40 41</td>
</tr>
</tbody>
</table>

**AV, aortic valve; CFD, computational fluid dynamics; CRT, cardiac resynchronisation therapy; CT (A), CT (angiography); DCM, dilated cardiomyopathy; FSI, fluid solid interaction; HCM, hypertrophic cardiomyopathy; HFREF, heart failure with preserved EF; HFRF, heart failure with reduced EF; MI, myocardial infarction; NH, neointimal hyperplasia; PAP, pulmonary artery pressure; PC, phase-contrast; PCI, percutaneous coronary intervention; RA, regulatory authority; RWMA, regional wall motion abnormality; (v)FFR, (virtual) fractional flow reserve; VAD, ventricular assist device; WSS, wall shear stress.**

Heart: first published as 10.1136/heartjnl-2015-308044 on 28 October 2015. Downloaded from http://heart.bmj.com/ on June 7, 2023 by guest. Protected by copyright.
5. Simulation

A computer file defining the physical parameters of the model is written. In addition to the geometric, discretisation and boundary data, this file must define properties including: blood density and viscosity (i.e., the fluid model), the initial conditions of the system (e.g., whether the fluid is initially static or moving), time discretisation information (time step size and numerical approximation schemes), and the desired output data (e.g., number of cardiac cycles to be simulated). This information allows the CFD solver to solve the Navier-Stokes and continuity equations, proceeding incrementally towards a final solution (‘convergence’). A typical 3D cardiovascular simulation involves >1 million elements run over several cardiac cycles, each divided into hundreds or thousands of individual time-steps. Millions of non-linear partial differential equations are solved simultaneously, and repeatedly, over all elements, at all time-steps. 3D CFD modelling is therefore time-consuming and computationally demanding.

6. Post-processing

Typically, the CFD solver produces the pressure and velocity field over all elements at each time-step. Only a small proportion of these data are of interest to the operator, so some post-processing is required to extract and display relevant data. A significant consideration in the development of these tools is the accuracy and reliability of the model. 3D CFD models are generally simple to use, but they require considerable skill and experience at each stage (especially steps 3–5) to ensure reliability of results. T"{u}r"{u}n, in particular, is prone to the development of shear stress, which can affect the accuracy of the results. Therefore, it is important that modelled results are validated against an acceptable standard. Commonly, this involves comparison with either values measured within an in vitro phantom or acquired during in vivo assessment. Validation generates confidence in the accuracy and reliability of a CFD model.

7. Validation

It is important that modelled results are validated against an acceptable standard. Commonly, this involves comparison with either values measured within an in vitro phantom or acquired during in vivo assessment. Validation generates confidence in the accuracy and reliability of a CFD model.

8. Boundary conditions

Collectively, the steps outlined above are known as a workflow or toolchain (see figure 1 and online supplementary video). Although there are many specialised software applications facilitating the construction and operation of CFD-based workflows, considerable effort and experience are required at each stage, especially steps 3–5, to ensure reliability of results.

**ADVANCED BOUNDARY CONDITIONS**

Rather than specifying pressure or flow at a boundary, an additional, lower-order model may be coupled to the 3D solver to generate more realistic conditions proximal and distal to the simulation domain. This method of modelling is efficient, because it allows detailed analysis in the 3D region without wasting high temporal and spatial refinement on regions beyond this. In some cases the model representing the distal boundary also provides proximal boundary condition. These closed-loop models, or system models, require very careful tuning.

**ASSUMPTIONS**

Many CFD models assume that the segmented region has rigid walls. Although untrue in the cardiovascular system, this...
approximation is acceptable for some applications. Vessel compliance allows blood to be stored during systole and released during diastole. At the system level this results in a finite speed of pressure wave transmission and tends to reduce the peak pressures associated with the inertial acceleration of the blood. Compliance tends to reduce shear stresses because the vessels are slightly larger when peak flow occurs. It is possible to model deformation of the wall, due to cardiac and respiratory variation, in response to change in pressure using fluid-solid interaction (FSI) models. These are far more complex to solve, boundary conditions are a challenge, and many wall parameters remain unknown, which increases the number of assumptions. Furthermore, it is yet to be established for which applications a full FSI approach improves accuracy. An example of the increased computational cost of FSI is reported by Brown et al where 3D transient (time-varying) analysis of the aorta required 145 h (FSI) compared with 6.6 h (CFD). An alternative is to impose wall movement derived from imaging data (eg, gated MRI). There are exciting developments in the use of data assimilation techniques in which sparse clinical data, for example, from 4D imaging, are integrated with the analysis process so that material properties of tissues in individual patients are recovered as the simulation progresses. In biomedical workflows it is assumed the boundaries of the fluid geometry are smooth, yet medical images may not generate smooth surfaces due to poor resolution or imaging artefacts. Instead, structures may be smoothed in silico after segmentation.

Typically, cardiovascular simulations assume blood behaves as an incompressible fluid. Although blood exhibits non-Newtonian behaviour (see glossary in table 2), which must be simulated for flow in small capillaries, in larger vessels these effects are often neglected and a Newtonian fluid model is assumed.

**BENEFITS OF CARDIOVASCULAR CFD MODELLING**

CFD modelling enables investigation of pressure and flow fields at a temporal and spatial resolution unachievable by any clinical methodology. Post-processing provides additional data, generating new insights into physiology and disease processes. For example, it is difficult, and invasive, to measure arterial wall shear stress (WSS), a key factor in the development of atherosclerosis and in-stent restenosis, whereas CFD models can compute WSS and map its spatial distribution. Such work has established the link between haemodynamic disturbance and atherogenesis and has explained the preferential deposition of atherosclerotic plaque at arterial bends and bifurcation regions. CFD modelling has been central to our current understanding of the effects of WSS on endothelial homeostasis: laminar, non-disturbed blood flow is associated with increased WSS which inhibits unnecessary endothelial cell activation; whereas turbulent or disturbed blood flow reduces WSS which stimulates adverse vessel remodelling. A complex series of WSS-related signalling pathways and interactions underlie this phenomenon. Before these pathways can be exploited to generate anti-atherosclerotic therapies their complexity needs to be

---

**Table 3** A summary of the various orders of CFD modelling applied to the cardiovascular system

<table>
<thead>
<tr>
<th>Model</th>
<th>Figure</th>
<th>CFD solution</th>
<th>Description/examples</th>
<th>Typical solution time†</th>
</tr>
</thead>
<tbody>
<tr>
<td>0D</td>
<td><img src="https://example.com/image1.png" alt="Image" /></td>
<td>No spatial dimension. Physiological variables are solved as a function of time (t), eg, $P_t = Q_t \cdot R_t$.</td>
<td>Lump together distributed physiological systems into a single description. They describe the global behaviour of the modelled segment. The 0D Windkessel model (pictured) is often used to represent the compliant and resistive nature of the arterial circulation. 0D models are frequently used to model components of the cardiovascular system or to improve boundary conditions for 3D models of arterial, venous or venous pathophysiology.</td>
<td>Immediate solution</td>
</tr>
<tr>
<td>1D</td>
<td><img src="https://example.com/image2.png" alt="Image" /></td>
<td>Physiological variables are solved as a function of a single spatial variable, typically length ($L_1$), eg, $P_{x,t} = Q_{x,t} \cdot R_{x,t}$.</td>
<td>Used to represent wave propagation characteristics and wave reflection. 1D models may also be used to provide boundary conditions for higher order models in order to increase refinement of the solution, especially where the effects of wave reflection are significant.</td>
<td>S (static) Min (transient)</td>
</tr>
<tr>
<td>2D</td>
<td><img src="https://example.com/image3.png" alt="Image" /></td>
<td>Physiological variables are solved as a function of two spatial variables, typically length and distance from centreline ($L_x$), eg, $P_{x,r,t} = Q_{x,r,t} \cdot R_{x,r,t}$.</td>
<td>Able to resolve the solution in 2D. Used less often now than previously due to ready availability of improved computer processing and 3D solvers. Examples include the simulation of para-prosthetic valve haemolysis and improvement of the assessment of the proximal flow convergence zone in the clinical evaluation of regurgitant valve disease.</td>
<td>Order of minutes for steady-state. Order of hours or days for transient.</td>
</tr>
<tr>
<td>3D</td>
<td><img src="https://example.com/image4.png" alt="Image" /></td>
<td>Physiological variables are solved as a function of all three spatial variables, including the angle around the centreline axis ($\theta$), eg, $P_{x,r,\theta,t} = Q_{x,r,\theta,t} \cdot R_{x,r,\theta,t}$.</td>
<td>Full 3D CFD can resolve the physiological solution in all dimensions including time. Examples are more widely reviewed in the main body of the text.</td>
<td></td>
</tr>
</tbody>
</table>

*Hydro-electrical analogue diagrams are often used to describe physiological components such as resistance, pressure (voltage), compliance (capacitance), and flow (current). Solution times vary according to complexity of the model and the mathematical solution. The times presented are approximate and are based on a model of coronary physiology. CFD, computational fluid dynamics; NS, Navier-Stokes; 0D, zero dimensional; 1D, one dimensional; 2D, two dimensional; 3D, three dimensional.

†Solution times vary according to complexity of the model and the mathematical solution. The times presented are approximate and are based on a model of coronary physiology.
better understood. Integrated multiscale CFD models provide a powerful tool to combine analysis of fluid mechanics and cellular response. Recently, the effect of disturbed WSS in stented vessels has been modelled to investigate the influence on both endothelial function and neointimal hyperplasia, which preferentially accumulates at regions of low and disturbed WSS (figure 3). Such models can be used to develop stents which minimise the risk of in-stent restenosis and thrombosis.

Device design
In silico methods allow rapid prototyping, with reduced risk to humans, so a priority for the medical devices industry is to replace expensive and time-consuming in vivo and in vitro experimentation with in silico testing. In recognition of this, the US Food and Drug Administration (FDA) issued draft guidance in 2014 on the use of modelling to support regulatory submissions. An example is the significant role which CFD plays in
design optimisation of mechanical heart valves.\textsuperscript{11} While comparison of major flow features captured in vitro with predictions from CFD shows good agreement, simulation delivers 3D information at much higher resolution within critical regions (eg, the hinges) than flow visualisation, giving invaluable insight into design-related thrombogenic potential.\textsuperscript{10} Comprehensive simulation of heart valve mechanics, including the separation of the upstream and downstream fluid regions at closure and the structural instability and snap-through dynamics of tissue valves, remain computationally challenging but achievable.\textsuperscript{9,13}

CFD has been used in the optimisation of several commercial ventricular assist devices (VADs), investigating potential thrombogenicity by highlighting design-related regions of stasis and device characteristics resulting in high shear stress.\textsuperscript{41} A tool for optimising thromboresistance has been recently demonstrated in a comparative study of two continuous flow VADs, which combines experimental and numerical simulation.\textsuperscript{40,57} Numerical models can also contribute to the process of VAD implantation, informing the choice of catheter implantation site.\textsuperscript{39}

In the context of stent design, the greatest emphasis has been on modelling the mechanical integrity of the stent structure during and after deployment. However, CFD provides a valuable tool to assess the resulting haemodynamics within the stented lesion.\textsuperscript{88} This, in turn, has been associated with the biological response of the vessel wall and the development of restenosis.\textsuperscript{27-29}

**Diagnostic tools and personalised medicine**

Computing intravascular physiology, with the aim of minimising invasive instrumentation, is of major interest. A prime example is fractional flow reserve (FFR), an index of physiological (coronary atherosclerosis) lesion significance, measured with a pressure-sensitive guidewire. FFR-guided therapy improves patient outcomes, reduces stent insertions, and reduces costs, yet it is used in <10% of cases due to a host of procedural and operator related factors.\textsuperscript{58} Several groups propose models for computing virtual FFR from angiography to provide the benefits of physiological assessment without the practical drawbacks which limit the invasive technique (see online supplementary figure S1).\textsuperscript{5,6,7,39} The VIRTU-1 trial demonstrated the effectiveness of CFD-derived FFR using invasive angiography (diagnostic accuracy 97\% vs invasive FFR).\textsuperscript{5} More recently, the HeartFlow-NXT trial demonstrated the performance of virtual FFR using CT coronary angiography (sensitivity 86\%, specificity 79\% vs invasive FFR).\textsuperscript{6} Both models offer a less invasive approach, neither requires hyperaemic flow induction nor the passage of an intracoronary wire, and taken together could offer the benefits of FFR to all patients being assessed for coronary artery disease (CAD).\textsuperscript{59,60} C\textsuperscript{2}FFR (HeartFlow Inc) is now FDA approved for use as a class II Coronary Physiologic Simulation Software Device.\textsuperscript{60}

Recent in vitro work combining CFD, colour Doppler and simulated Doppler images demonstrates the potential to reduce Doppler inter-user variability and inform interpretation of complex regurgitant flow fields in valvar heart disease.\textsuperscript{61} In silico models of the right heart and pulmonary arteries using phase-contrast MRI capture anatomical and flow velocity data to simulate pulmonary artery physiology.\textsuperscript{62} It is hoped that these models will soon deliver a diagnosis of pulmonary hypertension without invasive catheterisation.\textsuperscript{31} Added value may come from wave analysis of these models to discriminate between the key aetiological sub-groups of pulmonary hypertension.\textsuperscript{10}

Treatment decisions are often based upon the ‘gold standard’ of randomised controlled trials. Everyday clinical practice, however, requires tailored treatment for individual patients. CFD modelling offers a patient-specific approach to management, in which an individual’s unique anatomy and physiology are used to define the model. The impact of alternative intervention strategies can be compared and a personalised, optimised strategy selected.\textsuperscript{63} Patient-specific modelling will not diminish the need for clinical trials but will allow the delivery of truly objective, personalised management on a wide scale.

This approach is exemplified in aortic aneurysm management, where current simplistic guidelines use aneurysm diameter as the arbiter of treatment. The @neurIST project addresses this, and incorporates patient-specific anatomic, genomic and demographic data, with simulated flow patterns (figure 4), to calculate the risk of rupture.\textsuperscript{64} The optimal treatment of aortic type B...
dissections remains controversial. Thoracic endovascular aortic repair (TEVAR) carries a risk of spinal ischaemia, and multiple communicating channels between true and false lumens confer a risk of proximal rupture if only the primary entry is closed. Therefore, graft length is balanced against the risk of paraplegia. In this context, CFD modelling provides individualised risk stratification and optimised treatment delivery (figure 5).65 18 Similar simulations are useful in the context of abdominal aortic aneurysm.66 67

FULL SYSTEM MODELS: THE VIRTUAL PHYSIOLOGICAL HUMAN
There is increasing interest in integrating multiple physiological models into comprehensive system models to simulate the impact of various conditions, pathologies and treatments across multiple organ systems. While this is ambitious, large, international, collaborative research projects under the umbrella of the Virtual Physiological Human (VPH) reflect the seriousness, legitimacy and rationale underlying this long-term vision.68 Full system models offer the possibility of understanding, holistically, the impact of cardiovascular disease upon individual patients.

IN SILICO TRIALS
In silico techniques can simulate measures of safety, accuracy, and efficacy of interventions, both pharmacological and mechanical, in large cohorts of virtual patient models which represent naturally occurring physiological and pathological variability. This minimises the time, cost, and risk associated with clinical

Figure 3  A computational fluid dynamics (CFD) model demonstrating the correlation between wall shear stress (WSS) and restenosis in coronary artery disease. (A) Structural modelling of stent insertion in porcine coronary arteries reconstructed from micro-CT, and stent–artery coupling obtained after arterial recoil. (B) Comparison between the in vivo histological images (left) and corresponding sections from the structural simulation (right) demonstrating excellent agreement. (C) Results of the CFD simulations in terms of the spatial distribution of WSS magnitude over the arterial wall. (D) The correlation between areas characterised by low WSS (orange lines) and in-stent restenosis after 14 days. The CFD simulation of WSS has identified areas of reduced shear and restenosis with excellent agreement. Figure reproduced from Morlacchi et al26 with kind permission from Springer Science and Business Media.

Figure 4  Computational fluid dynamics (CFD) model of an intracranial berry aneurysm from the @neurist project. Panel (A) demonstrates the reconstructed surface mesh. Panels (B) and (C) demonstrate the CFD simulated pressure (B) and wall shear stress (C) acting upon the aneurysm wall, which may be useful in predicting risk of rupture on a patient-specific basis.
trials. The Avicenna project leverages significant commercial interest and engagement to develop a ‘roadmap’ describing the route by which multi-scale in silico techniques can achieve this.69

CHALLENGES AND LIMITATIONS

CFD models in medicine have traditionally been used by two user groups: industrial medical device developers, in rapid, low-cost, device prototyping; and academics, to investigate cardiovascular physiology and compute parameters that cannot otherwise be obtained. Both groups construct models which are typically complex, involve multiple finely-tuned geometric, haemodynamic and material parameters and require long computation times. In contrast, clinicians are a third, emerging user group, who require rapid results with adequate accuracy.

Model accuracy is determined by model design and quality of input data. For CFD applications it is unclear how detailed the clinical data needs to be in terms of geometry (segmented from medical images) and parameterisation (variability described by the model and the tuning of patient-specific boundary conditions). Continuing improvements in imaging, image-registration and segmentation algorithms will augment accuracy.50 Model parameterisation is more challenging, because it requires detailed knowledge of physiological metrics in the proximal and distal circulations which may be inaccessible and variable in health and in disease, for example, microcirculatory resistance is a major determinant of coronary blood flow. Further understanding of the relative importance of physiological parameters is required to determine those which are most influential, and those which can be assumed or averaged.70 This allows
unnecessary model complexity to be simplified, balancing computing speed against accuracy. A second challenge is the development of relevant industry standards. In the European Union and USA, diagnostic software is regulated via CE marking and FDA directives, respectively; but there are no industry standards governing accuracy, reliability or validation. The FDA is addressing this through benchmarking initiatives, in the same way that aviation authorities adopted computer-aided design over traditional physical testing. Third, large volumes of clinical data, of value for model development and validation, are stored in hospital systems. Access is variable and restrictive; although the VPH-Share project demonstrates how anonymised patient-specific data and in silico models can be shared securely. Access to such data supports model validation against long-term outcomes which may expedite clinical translation. Fourth, CFD modelling can be perceived as a ‘disruptive technology’, and a threat, especially by manufacturers of traditional hardware. Finally, the next generation of doctors will require training in silico systems, and understanding their principles, methodologies and limitations. Several initiatives are attempting to address this, but in the longer term, in silico medicine may gain prominence in medical curricula.

**FUTURE DIRECTIONS**

In the context of device development, the major computational modelling and technological challenges have already been addressed and the benefits of simulation are recognised by the regulatory authorities. Sustained investment will enable engineers to continue model refinement and the development of novel applications, specifically targeting increases in precision, personalisation and speed. Beyond technological development, and before these tools become established in routine clinical practice, the most immediate need is to demonstrate equivalence of in silico results relative to invasive measurements through observational trials. Beyond this, efficacy must be demonstrated in large multicentre clinical trials. It is clear that these techniques have the potential to change clinical practice. The beneficiaries will be patients, clinicians and healthcare providers.

**Acknowledgements** Dr Morris is funded by a Clinical Research Training Fellowship from the British Heart Foundation. Figure 4 was kindly provided by Dr Alberto Marzo, University of Sheffield.

**Contributors** All authors have made a substantial contribution to the conception or design of the work, the drafting and revision of the work and have made an intellectual contribution. All authors have given final approval of the version submitted and have agreed to be accountable for all aspects of the work.

**Funding** British Heart Foundation (R/134747-11-1).

**Competing interests** None declared.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.  

**REFERENCES**

51 U.S. Food and Drug Administration. De novo classification request for FFRT V. 1.4 (De Novo Summary (BEN30045)). 2014.

Review